Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

23.39 +0.43 (+1.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,693,637
Open 23.09
Bid (Size) 22.29 (1)
Ask (Size) 23.50 (5)
Prev. Close 22.96
Today's Range 22.80 - 23.50
52wk Range 18.64 - 24.34
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
From Exelixis, Inc.
Via Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
Via Chartmill

Performance

YTD
-2.26%
-2.26%
1 Month
+5.08%
+5.08%
3 Month
-0.59%
-0.59%
6 Month
+5.89%
+5.89%
1 Year
+18.01%
+18.01%

More News

Read More
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
Via Benzinga
Technical Signals Point to a Possible Breakout for EXELIXIS INC.
Via Chartmill
What Analysts Are Saying About Exelixis Stock
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
From Exelixis, Inc.
Via Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Via The Motley Fool
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Via Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Via InvestorPlace
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
The Top 3 Biotech Stocks to Buy in April 2024
Via InvestorPlace
NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
From Exelixis, Inc.
Via Business Wire
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
Via Chartmill
3 Biotech Stocks to Buy on the Dip: March 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.